| 产品描述: | MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx. |
| 体外研究: |
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells[1]. MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD)[1]. |
| 体内研究: |
MLN3126 inhibits CCL25-induced calcium mobilization with an IC50 value of 6.3 nM in CCR9 expressing cells. MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50 of 14.2 nM. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.238 ml |
11.188 ml |
22.376 ml |
| 5 mM |
0.448 ml |
2.238 ml |
4.475 ml |
| 10 mM |
0.224 ml |
1.119 ml |
2.238 ml |
| 50 mM |
0.045 ml |
0.224 ml |
0.448 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |